Ontology type: schema:ScholarlyArticle
2020-09-05
AUTHORS ABSTRACTAllograft rejection-related acute and chronic heart failure (HF) is a major cause of death in heart transplant recipients. Given the deleterious impact of late recognized acute rejection (AR) or non-recognized asymptomatic antibody-mediated rejection on short- and long-term allograft function improvement of AR surveillance and optimization of action strategies for confirmed AR can prevent AR-related allograft failure and delay the development of cardiac allograft vasculopathy, which is the major cause for HF after the first posttransplant year. Routine non-invasive monitoring of cardiac function can improve both detection and functional severity grading of AR. It can also be helpful in guiding the anti-AR therapy and timing of routine surveillance endomyocardial biopsies (EMBs). The combined use of EMBs with non-invasive technologies and methods, which allow detection of subclinical alterations in myocardial function (e.g., tissue Doppler imaging and speckle-tracking echocardiography), reveal alloimmune activation (e.g., screening of complement-activating donor-specific antibodies and circulating donor-derived cell-free DNA) and help in predicting the imminent risk of immune-mediated injury (e.g., gene expression profiling, screening of non-HLA antibodies, and circulating donor-derived cell-free DNA), can ensure the best possible surveillance and management of AR. This article gives an overview of the current knowledge about the reliability and clinical value of non-invasive cardiac allograft AR surveillance. Particular attention is focused on the potential usefulness of non-invasive tools and techniques for detection and functional grading of early and late ARs in asymptomatic patients. Overall, the review aimed to provide a theoretical and practical basis for those engaged in this particularly demanding up-to-date topic. More... »
PAGES319-336
http://scigraph.springernature.com/pub.10.1007/s10741-020-10023-3
DOIhttp://dx.doi.org/10.1007/s10741-020-10023-3
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1130621179
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/32889634
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Cardio Centrum Berlin, 10117, Berlin, Germany",
"id": "http://www.grid.ac/institutes/None",
"name": [
"German Centre for Heart and Circulatory Research (DZHK), Partner Site Berlin, Berlin, Germany",
"Cardio Centrum Berlin, 10117, Berlin, Germany"
],
"type": "Organization"
},
"familyName": "Dandel",
"givenName": "Michael",
"id": "sg:person.0651541033.04",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651541033.04"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Cardio Centrum Berlin, 10117, Berlin, Germany",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Cardio Centrum Berlin, 10117, Berlin, Germany"
],
"type": "Organization"
},
"familyName": "Hetzer",
"givenName": "Roland",
"id": "sg:person.01365311760.42",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365311760.42"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/nm1201-1347",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1011016385",
"https://doi.org/10.1038/nm1201-1347"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s40472-015-0081-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015624680",
"https://doi.org/10.1007/s40472-015-0081-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00330-014-3246-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1020963245",
"https://doi.org/10.1007/s00330-014-3246-2"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00246-005-1155-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1002407353",
"https://doi.org/10.1007/s00246-005-1155-5"
],
"type": "CreativeWork"
}
],
"datePublished": "2020-09-05",
"datePublishedReg": "2020-09-05",
"description": "Allograft rejection-related acute and chronic heart failure (HF) is a major cause of death in heart transplant recipients. Given the deleterious impact of late recognized acute rejection (AR) or non-recognized asymptomatic antibody-mediated rejection on short- and long-term allograft function improvement of AR surveillance and optimization of action strategies for confirmed AR can prevent AR-related allograft failure and delay the development of cardiac allograft vasculopathy, which is the major cause for HF after the first posttransplant year. Routine non-invasive monitoring of cardiac function can improve both detection and functional severity grading of AR. It can also be helpful in guiding the anti-AR therapy and timing of routine surveillance endomyocardial biopsies (EMBs). The combined use of EMBs with non-invasive technologies and methods, which allow detection of subclinical alterations in myocardial function (e.g., tissue Doppler imaging and speckle-tracking echocardiography), reveal alloimmune activation (e.g., screening of complement-activating donor-specific antibodies and circulating donor-derived cell-free DNA) and help in predicting the imminent risk of immune-mediated injury (e.g., gene expression profiling, screening of non-HLA antibodies, and circulating donor-derived cell-free DNA), can ensure the best possible surveillance and management of AR. This article gives an overview of the current knowledge about the reliability and clinical value of non-invasive cardiac allograft AR surveillance. Particular attention is focused on the potential usefulness of non-invasive tools and techniques for detection and functional grading of early and late ARs in asymptomatic patients. Overall, the review aimed to provide a theoretical and practical basis for those engaged in this particularly demanding up-to-date topic.",
"genre": "article",
"id": "sg:pub.10.1007/s10741-020-10023-3",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1115887",
"issn": [
"1382-4147",
"1573-7322"
],
"name": "Heart Failure Reviews",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "2",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "26"
}
],
"keywords": [
"acute rejection",
"heart failure",
"endomyocardial biopsy",
"clinical value",
"asymptomatic antibody-mediated rejection",
"routine surveillance endomyocardial biopsies",
"major cause",
"anti-AR therapy",
"late acute rejection",
"chronic heart failure",
"heart transplant recipients",
"antibody-mediated rejection",
"cardiac allograft vasculopathy",
"first posttransplant year",
"surveillance endomyocardial biopsies",
"alloimmune activation",
"transplant recipients",
"allograft failure",
"allograft vasculopathy",
"posttransplant year",
"subclinical alterations",
"non-invasive tool",
"asymptomatic patients",
"cardiac function",
"myocardial function",
"function improvement",
"AR surveillance",
"severity grading",
"non-invasive monitoring",
"non-invasive technology",
"possible surveillance",
"surveillance",
"imminent risk",
"current knowledge",
"grading",
"cause",
"potential usefulness",
"failure",
"deleterious impact",
"combined use",
"vasculopathy",
"allografts",
"biopsy",
"patients",
"therapy",
"injury",
"functional grading",
"rejection",
"recipients",
"prevention",
"death",
"risk",
"alterations",
"activation",
"review",
"years",
"detection",
"function",
"management",
"usefulness",
"timing",
"improvement",
"monitoring",
"use",
"date topic",
"values",
"development",
"strategies",
"particular attention",
"knowledge",
"impact",
"action strategies",
"reliability",
"overview",
"tool",
"basis",
"attention",
"technique",
"article",
"method",
"practical basis",
"topic",
"technology",
"optimization"
],
"name": "Non-invasive cardiac allograft rejection surveillance: reliability and clinical value for prevention of heart failure",
"pagination": "319-336",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1130621179"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s10741-020-10023-3"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"32889634"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s10741-020-10023-3",
"https://app.dimensions.ai/details/publication/pub.1130621179"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-10T10:28",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_842.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s10741-020-10023-3"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10741-020-10023-3'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10741-020-10023-3'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10741-020-10023-3'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10741-020-10023-3'
This table displays all metadata directly associated to this object as RDF triples.
170 TRIPLES
22 PREDICATES
113 URIs
101 LITERALS
7 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1007/s10741-020-10023-3 | schema:about | anzsrc-for:11 |
2 | ″ | ″ | anzsrc-for:1102 |
3 | ″ | schema:author | N30812eb6678947079da848931f6fc7cd |
4 | ″ | schema:citation | sg:pub.10.1007/s00246-005-1155-5 |
5 | ″ | ″ | sg:pub.10.1007/s00330-014-3246-2 |
6 | ″ | ″ | sg:pub.10.1007/s40472-015-0081-6 |
7 | ″ | ″ | sg:pub.10.1038/nm1201-1347 |
8 | ″ | schema:datePublished | 2020-09-05 |
9 | ″ | schema:datePublishedReg | 2020-09-05 |
10 | ″ | schema:description | Allograft rejection-related acute and chronic heart failure (HF) is a major cause of death in heart transplant recipients. Given the deleterious impact of late recognized acute rejection (AR) or non-recognized asymptomatic antibody-mediated rejection on short- and long-term allograft function improvement of AR surveillance and optimization of action strategies for confirmed AR can prevent AR-related allograft failure and delay the development of cardiac allograft vasculopathy, which is the major cause for HF after the first posttransplant year. Routine non-invasive monitoring of cardiac function can improve both detection and functional severity grading of AR. It can also be helpful in guiding the anti-AR therapy and timing of routine surveillance endomyocardial biopsies (EMBs). The combined use of EMBs with non-invasive technologies and methods, which allow detection of subclinical alterations in myocardial function (e.g., tissue Doppler imaging and speckle-tracking echocardiography), reveal alloimmune activation (e.g., screening of complement-activating donor-specific antibodies and circulating donor-derived cell-free DNA) and help in predicting the imminent risk of immune-mediated injury (e.g., gene expression profiling, screening of non-HLA antibodies, and circulating donor-derived cell-free DNA), can ensure the best possible surveillance and management of AR. This article gives an overview of the current knowledge about the reliability and clinical value of non-invasive cardiac allograft AR surveillance. Particular attention is focused on the potential usefulness of non-invasive tools and techniques for detection and functional grading of early and late ARs in asymptomatic patients. Overall, the review aimed to provide a theoretical and practical basis for those engaged in this particularly demanding up-to-date topic. |
11 | ″ | schema:genre | article |
12 | ″ | schema:inLanguage | en |
13 | ″ | schema:isAccessibleForFree | false |
14 | ″ | schema:isPartOf | N38730dbe7abf4e639040b072d696ea1f |
15 | ″ | ″ | N59a8923b354441409062010debc966a3 |
16 | ″ | ″ | sg:journal.1115887 |
17 | ″ | schema:keywords | AR surveillance |
18 | ″ | ″ | action strategies |
19 | ″ | ″ | activation |
20 | ″ | ″ | acute rejection |
21 | ″ | ″ | allograft failure |
22 | ″ | ″ | allograft vasculopathy |
23 | ″ | ″ | allografts |
24 | ″ | ″ | alloimmune activation |
25 | ″ | ″ | alterations |
26 | ″ | ″ | anti-AR therapy |
27 | ″ | ″ | antibody-mediated rejection |
28 | ″ | ″ | article |
29 | ″ | ″ | asymptomatic antibody-mediated rejection |
30 | ″ | ″ | asymptomatic patients |
31 | ″ | ″ | attention |
32 | ″ | ″ | basis |
33 | ″ | ″ | biopsy |
34 | ″ | ″ | cardiac allograft vasculopathy |
35 | ″ | ″ | cardiac function |
36 | ″ | ″ | cause |
37 | ″ | ″ | chronic heart failure |
38 | ″ | ″ | clinical value |
39 | ″ | ″ | combined use |
40 | ″ | ″ | current knowledge |
41 | ″ | ″ | date topic |
42 | ″ | ″ | death |
43 | ″ | ″ | deleterious impact |
44 | ″ | ″ | detection |
45 | ″ | ″ | development |
46 | ″ | ″ | endomyocardial biopsy |
47 | ″ | ″ | failure |
48 | ″ | ″ | first posttransplant year |
49 | ″ | ″ | function |
50 | ″ | ″ | function improvement |
51 | ″ | ″ | functional grading |
52 | ″ | ″ | grading |
53 | ″ | ″ | heart failure |
54 | ″ | ″ | heart transplant recipients |
55 | ″ | ″ | imminent risk |
56 | ″ | ″ | impact |
57 | ″ | ″ | improvement |
58 | ″ | ″ | injury |
59 | ″ | ″ | knowledge |
60 | ″ | ″ | late acute rejection |
61 | ″ | ″ | major cause |
62 | ″ | ″ | management |
63 | ″ | ″ | method |
64 | ″ | ″ | monitoring |
65 | ″ | ″ | myocardial function |
66 | ″ | ″ | non-invasive monitoring |
67 | ″ | ″ | non-invasive technology |
68 | ″ | ″ | non-invasive tool |
69 | ″ | ″ | optimization |
70 | ″ | ″ | overview |
71 | ″ | ″ | particular attention |
72 | ″ | ″ | patients |
73 | ″ | ″ | possible surveillance |
74 | ″ | ″ | posttransplant year |
75 | ″ | ″ | potential usefulness |
76 | ″ | ″ | practical basis |
77 | ″ | ″ | prevention |
78 | ″ | ″ | recipients |
79 | ″ | ″ | rejection |
80 | ″ | ″ | reliability |
81 | ″ | ″ | review |
82 | ″ | ″ | risk |
83 | ″ | ″ | routine surveillance endomyocardial biopsies |
84 | ″ | ″ | severity grading |
85 | ″ | ″ | strategies |
86 | ″ | ″ | subclinical alterations |
87 | ″ | ″ | surveillance |
88 | ″ | ″ | surveillance endomyocardial biopsies |
89 | ″ | ″ | technique |
90 | ″ | ″ | technology |
91 | ″ | ″ | therapy |
92 | ″ | ″ | timing |
93 | ″ | ″ | tool |
94 | ″ | ″ | topic |
95 | ″ | ″ | transplant recipients |
96 | ″ | ″ | use |
97 | ″ | ″ | usefulness |
98 | ″ | ″ | values |
99 | ″ | ″ | vasculopathy |
100 | ″ | ″ | years |
101 | ″ | schema:name | Non-invasive cardiac allograft rejection surveillance: reliability and clinical value for prevention of heart failure |
102 | ″ | schema:pagination | 319-336 |
103 | ″ | schema:productId | N29ee347077ac42be91868d02257b13ba |
104 | ″ | ″ | N313c81d039d944efbbb9280997e46f81 |
105 | ″ | ″ | N68dcc0c545ad4f0db63b1aca213a7198 |
106 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1130621179 |
107 | ″ | ″ | https://doi.org/10.1007/s10741-020-10023-3 |
108 | ″ | schema:sdDatePublished | 2022-05-10T10:28 |
109 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
110 | ″ | schema:sdPublisher | Nd8bfcd5767c74b79a69660980fe7fa73 |
111 | ″ | schema:url | https://doi.org/10.1007/s10741-020-10023-3 |
112 | ″ | sgo:license | sg:explorer/license/ |
113 | ″ | sgo:sdDataset | articles |
114 | ″ | rdf:type | schema:ScholarlyArticle |
115 | N29ee347077ac42be91868d02257b13ba | schema:name | doi |
116 | ″ | schema:value | 10.1007/s10741-020-10023-3 |
117 | ″ | rdf:type | schema:PropertyValue |
118 | N30812eb6678947079da848931f6fc7cd | rdf:first | sg:person.0651541033.04 |
119 | ″ | rdf:rest | N3b77387180524e9b8a6b2e529b9ebd24 |
120 | N313c81d039d944efbbb9280997e46f81 | schema:name | pubmed_id |
121 | ″ | schema:value | 32889634 |
122 | ″ | rdf:type | schema:PropertyValue |
123 | N38730dbe7abf4e639040b072d696ea1f | schema:issueNumber | 2 |
124 | ″ | rdf:type | schema:PublicationIssue |
125 | N3b77387180524e9b8a6b2e529b9ebd24 | rdf:first | sg:person.01365311760.42 |
126 | ″ | rdf:rest | rdf:nil |
127 | N59a8923b354441409062010debc966a3 | schema:volumeNumber | 26 |
128 | ″ | rdf:type | schema:PublicationVolume |
129 | N68dcc0c545ad4f0db63b1aca213a7198 | schema:name | dimensions_id |
130 | ″ | schema:value | pub.1130621179 |
131 | ″ | rdf:type | schema:PropertyValue |
132 | Nd8bfcd5767c74b79a69660980fe7fa73 | schema:name | Springer Nature - SN SciGraph project |
133 | ″ | rdf:type | schema:Organization |
134 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
135 | ″ | schema:name | Medical and Health Sciences |
136 | ″ | rdf:type | schema:DefinedTerm |
137 | anzsrc-for:1102 | schema:inDefinedTermSet | anzsrc-for: |
138 | ″ | schema:name | Cardiorespiratory Medicine and Haematology |
139 | ″ | rdf:type | schema:DefinedTerm |
140 | sg:journal.1115887 | schema:issn | 1382-4147 |
141 | ″ | ″ | 1573-7322 |
142 | ″ | schema:name | Heart Failure Reviews |
143 | ″ | schema:publisher | Springer Nature |
144 | ″ | rdf:type | schema:Periodical |
145 | sg:person.01365311760.42 | schema:affiliation | grid-institutes:None |
146 | ″ | schema:familyName | Hetzer |
147 | ″ | schema:givenName | Roland |
148 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365311760.42 |
149 | ″ | rdf:type | schema:Person |
150 | sg:person.0651541033.04 | schema:affiliation | grid-institutes:None |
151 | ″ | schema:familyName | Dandel |
152 | ″ | schema:givenName | Michael |
153 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651541033.04 |
154 | ″ | rdf:type | schema:Person |
155 | sg:pub.10.1007/s00246-005-1155-5 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1002407353 |
156 | ″ | ″ | https://doi.org/10.1007/s00246-005-1155-5 |
157 | ″ | rdf:type | schema:CreativeWork |
158 | sg:pub.10.1007/s00330-014-3246-2 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1020963245 |
159 | ″ | ″ | https://doi.org/10.1007/s00330-014-3246-2 |
160 | ″ | rdf:type | schema:CreativeWork |
161 | sg:pub.10.1007/s40472-015-0081-6 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1015624680 |
162 | ″ | ″ | https://doi.org/10.1007/s40472-015-0081-6 |
163 | ″ | rdf:type | schema:CreativeWork |
164 | sg:pub.10.1038/nm1201-1347 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1011016385 |
165 | ″ | ″ | https://doi.org/10.1038/nm1201-1347 |
166 | ″ | rdf:type | schema:CreativeWork |
167 | grid-institutes:None | schema:alternateName | Cardio Centrum Berlin, 10117, Berlin, Germany |
168 | ″ | schema:name | Cardio Centrum Berlin, 10117, Berlin, Germany |
169 | ″ | ″ | German Centre for Heart and Circulatory Research (DZHK), Partner Site Berlin, Berlin, Germany |
170 | ″ | rdf:type | schema:Organization |